New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
10:00 EDTSIX, CLNE, PANW, UNH, MPLX, COV, BSX, MDCO, JNJ, COH, AET, TDC, RLGY, ISRG, CFNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aetna (AET) initiated with a Buy at Lazard Capital... Boston Scientific (BSX) initiated with a Buy at Stifel Nicolaus... CareFusion (CFN) initiated with a Buy at Stifel Nicolaus... Coach (COH) initiated with an Outperform at Wells Fargo... Covidien (COV) initiated with a Buy at Brean Capital... Intuitive Surgical (ISRG) initiated with a Hold at Stifel Nicolaus... Johnson & Johnson (JNJ) initiated with a Hold at Stifel Nicolaus... MPLX (MPLX) initiated with a Neutral at UBS... Realogy (RLGY) initiated with a Neutral at Goldman... The Medicines Co. (MDCO) initiated with an Outperform at Oppenheimer... UnitedHealth (UNH) initiated with a Buy at Lazard Capital... Teradata (TDC) initiated with an Outperform at Credit Suisse... Six Flags (SIX) initiated with a Neutral at Longbow... Palo Alto (PANW) initiated with a Neutral at Nomura... Clean Energy (CLNE) initiated with a Buy at Dougherty.
News For AET;BSX;CFN;COH;COV;ISRG;JNJ;MPLX;RLGY;MDCO;UNH;TDC;SIX;PANW;CLNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 10, 2014
14:45 EDTAET, UNHDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
08:16 EDTPANWBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 10 at 10:40 am; not all company presentations may be webcasted.Webcast Link
08:12 EDTPANWIT security outlook remains positive, says Pacific Crest
Subscribe for More Information
07:38 EDTBSXBoston Scientific management to meet with Deutsche Bank
Subscribe for More Information
06:01 EDTBSXBoston Scientific implied volatility of 38 at upper end of index mean range
December 9, 2014
14:22 EDTAETAetna updates clinical policy for H.P. Acthar Gel
Subscribe for More Information
10:27 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
10:23 EDTCOHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:05 EDTCOHCoach initiated with an Equal Weight at Stephens
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:42 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:00 EDTCLNEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:31 EDTCFNBecton Dickinson and CareFusion sets date for special meeting in proposed merger
Becton, Dickinson (BDX) and CareFusion (CFN) announced that CareFusion expects to hold a special meeting on January 21, 2015 for CareFusion stockholders to consider and vote upon the proposed merger of CareFusion and BD. As previously announced on October 5, 2014, BD and CareFusion entered into a definitive agreement pursuant to which BD would acquire CareFusion in a stock and cash transaction. CareFusion stockholder approval is a condition to the merger. In addition to CareFusion stockholder approval, the proposed acquisition remains subject to certain other conditions and approvals, including approval of the proposed acquisition by the European Commission under the European Union Merger Regulation. CareFusion has fixed the close of business on December 18, 2014 as the record date for the purpose of determining the stockholders who are entitled to notice of, and to vote at, the special meeting.
08:13 EDTCFNCareFusion announces agreement with Medacist
Subscribe for More Information
05:53 EDTBSXStocks with implied volatility movement; BSX BMY
Subscribe for More Information
05:42 EDTCLNEClean Energy downgraded to Hold from Buy at Ascendiant
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use